

Andreas Pfätzner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8322852/publications.pdf>

Version: 2024-02-01

55
papers

1,879
citations

361413

20
h-index

254184

43
g-index

58
all docs

58
docs citations

58
times ranked

2234
citing authors

#	ARTICLE	IF	CITATIONS
1	Laboratory Protocol and Pilot Results for Dynamic Interference Testing of Continuous Glucose Monitoring Sensors. <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 59-65.	2.2	4
2	The Diabetes Technology Society Green Declaration. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 215-217.	2.2	4
3	Re: "Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity". <i>Public Health</i> , 2021, 199, e1.	2.9	2
4	System Accuracy Assessment of a Combined Invasive and Noninvasive Glucometer. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 575-581.	2.2	4
5	Why Do People With Diabetes Have a High Risk for Severe COVID-19 Disease?" A Dental Hypothesis and Possible Prevention Strategy. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 769-771.	2.2	22
6	System accuracy assessments with a blood glucose meter with combined glucose and Å-hydroxybutyrate measurement capabilities. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1043-1048.	3.1	3
7	Laboratory Evaluation of Linearity, Repeatability, and Hematocrit Interference With an Internet-Enabled Blood Glucose Meter. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 514-521.	2.2	6
8	System Accuracy Assessment of a Blood Glucose Meter With Wireless Internet Access Associated With Unusual Hypoglycemia Patterns in Clinical Trials. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 507-513.	2.2	8
9	Evaluation of a New Noninvasive Glucose Monitoring Device by Means of Standardized Meal Experiments. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 1178-1183.	2.2	24
10	Technology-derived storage solutions for stabilizing insulin in extreme weather conditions I: the ViViCap-1 device. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 709-714.	5.0	1
11	Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy"an emerging problem and solutions offered by diabetes technology. <i>Endocrine</i> , 2017, 56, 212-216.	2.3	30
12	Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 278-283.	2.2	4
13	Identification of Highly Specific scFvs against Total Adiponectin for Diagnostic Purposes. <i>Biology</i> , 2017, 6, 26.	2.8	0
14	Mesenchymal Stem Cell Differentiation into Adipocytes Is Equally Induced by Insulin and Proinsulin <i>in Vitro</i> . <i>International Journal of Stem Cells</i> , 2017, 10, 154-159.	1.8	7
15	Longer Usage Time for CSII Catheters. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 987-988.	2.2	0
16	Successful Performance of Laboratory Investigations with Blood Glucose Meters Employing a Dynamic Electrochemistry-Based Correction Algorithm Is Dependent on Careful Sample Handling. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 650-656.	4.4	8
17	Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1122-1129.	2.2	10
18	Advances in Patient Self-Monitoring of Blood Glucose. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 101-103.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Evaluation of System Accuracy of the GlucoMen LX Plus Blood Glucose Monitoring System With Reference to ISO 15197:2013. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 618-619.	2.2	3
20	Diabetes Technology. <i>Endocrine Development</i> , 2016, 31, 57-83.	1.3	0
21	Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 1292-1298.	2.2	43
22	Evaluation of Hematocrit Interference With MyStar Extra and Seven Competitive Devices. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 262-267.	2.2	15
23	A New Metabolite Panel Test for Identification of Patients With Impaired Glucose Tolerance? Analysis of the Article by Cobb et al. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 77-79.	2.2	0
24	Elevated Intact Proinsulin Levels During an Oral Glucose Challenge Indicate Progressive β -Cell Dysfunction and May Be Predictive for Development of Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 1307-1312.	2.2	9
25	Improved Insulin Absorption by Means of Standardized Injection Site Modulation Results in a Safer and More Efficient Prandial Insulin Treatment A Review of the Existing Clinical Data. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 116-122.	2.2	5
26	Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control. <i>Current Medical Research and Opinion</i> , 2014, 30, 2001-2008.	1.9	5
27	Performance of blood glucose meters in compliance with current and future clinical ISO15197 accuracy criteria. <i>Current Medical Research and Opinion</i> , 2014, 30, 185-190.	1.9	16
28	The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2014, 30, 753-760.	1.9	11
29	Blood Glucose Meters Employing Dynamic Electrochemistry are Stable against Hematocrit Interference in a Laboratory Setting. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 1530-1537.	2.2	12
30	Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 576-579.	4.4	20
31	Hematocrit Interference of Blood Glucose Meters for Patient Self-Measurement. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 179-189.	2.2	51
32	Technical Aspects of the Parkes Error Grid. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 1275-1281.	2.2	81
33	Determination of Hematocrit Interference in Blood Samples Derived from Patients with Different Blood Glucose Concentrations. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 170-178.	2.2	16
34	In Type 2 Diabetes Patients, Insulin Glargine is Associated with Lower Postprandial Release of Intact Proinsulin Compared with Sulfonylurea Treatment. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 634-640.	2.2	10
35	Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. <i>Diabetic Medicine</i> , 2012, 29, 1115-1118.	2.3	60
36	Dynamic Electrochemistry Corrects for Hematocrit Interference on Blood Glucose Determinations with Patient Self-Measurement Devices. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 1167-1175.	2.2	40

#	ARTICLE	IF	CITATIONS
37	Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 116-120.	8.6	20
38	Pilot Study for Assessment of Optimal Frequency for Changing Catheters in Insulin Pump Therapy—Trouble Starts on Day 3. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 976-982.	2.2	81
39	Cardiovascular Effects of Disturbed Insulin Activity in Metabolic Syndrome and in Type 2 Diabetic Patients. <i>Hormone and Metabolic Research</i> , 2009, 41, 123-131.	1.5	34
40	Effect of Insulin Glulisine on Microvascular Blood Flow and Endothelial Function in the Postprandial State. <i>Diabetes Care</i> , 2008, 31, 1021-1025.	8.6	17
41	A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus. <i>Clinical Laboratory</i> , 2008, 54, 485-90.	0.5	14
42	Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 303-312.	2.4	1
43	Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 445-459.	1.5	34
44	High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2006, 8, 28-36.	4.4	167
45	Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 20-25.	3.4	223
46	The Switch from Sulfonylurea to Preprandial Short-Acting Insulin Analog Substitution Has an Immediate and Comprehensive β -Cell Protective Effect in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2006, 8, 375-384.	4.4	19
47	IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 478-486.	4.4	26
48	Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1925-1931.	2.8	270
49	Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. <i>Clinical Laboratory</i> , 2005, 51, 243-9.	0.5	9
50	Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. <i>Clinical Laboratory</i> , 2005, 51, 489-94.	0.5	49
51	Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2004, 6, 405-412.	4.4	44
52	Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 682-687.	8.6	139
53	Clinical and Laboratory Evaluation of Specific Chemiluminescence Assays for Intact and Total Proinsulin. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1234-8.	2.3	22
54	Investigation on the accuracy of the blood glucose monitoring device Prestige IQ. <i>Diabetes, Nutrition & Metabolism</i> , 2003, 16, 257-61.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.. Diabetes Care, 1999, 22, 784-788.	8.6	166